Indivior posted record quarterly and full-year performance anchored by Sublocade, its long-acting buprenorphine injection for opioid use disorder. Total Sublocade net revenue reached $856 million in 2025, up 13% year over year, with fourth-quarter revenue up 30% to $252 million. Adjusted EBITDA rose 20% to $428 million for the year and 91% in the fourth quarter to $142 million. The company reaffirmed 2026 guidance, targeting $905–$945 million in Sublocade revenue and $535–$575 million in adjusted EBITDA, capped non-GAAP operating expenses at $450 million, and initiated a new $400 million share repurchase program. It also completed a redomiciliation to the United States, closed out its legacy DOJ obligation, and launched a nationwide DTC campaign in October to expand awareness of long-acting injectables in OUD.
The strategic read-through is clear: Indivior has recut itself as a focused, cash-generative specialty business built around a single high-conviction growth engine. With operating discipline, a cleaner legal overhang, and an investor-friendly U.S. listing and index inclusion, the company is pursuing a tight loop of category shaping, payer optimization, and capital returns. The live question is whether it can translate policy and awareness tailwinds into sustained mid-teens unit growth in 2026 while defending share against emerging LAI competitors and navigating site-of-care bottlenecks that often slow medical-benefit therapies.
This matters now because the OUD treatment landscape is at an inflection point. Daily sublingual therapies are cheap and ubiquitous, but adherence and diversion challenges remain pervasive; LAIs promise retention and stability that matter for patients, providers, and public health programs. For payers, the calculus hinges on real-world reductions in relapse, ER utilization, and justice-system interaction that justify higher upfront costs and support broader Medicaid and commercial coverage. For HCPs and treatment networks, growth will depend on practice workflows, buy-and-bill confidence, reimbursement reliability, and care delivery in settings like community mental health centers and carceral health. Indivior’s 2025 unit growth of 7% for the year and 12% in Q4 signals momentum, but the reliance on gross-to-net benefits underscores the need to keep expanding prescriber capacity and reducing administrative friction.
The company’s portfolio pruning—winding down promotion for Perseris and Opvee—reinforces a wider industry trend toward concentration on lead assets with clear payer line of sight. At the same time, LAIs are winning share across psychiatry and infectious disease, and OUD is moving from waiver-gated specialty prescribing to mainstream primary care following recent regulatory shifts. Indivior’s DTC push in a stigmatized, high-need category is an aggressive bet that patient activation can pull through provider adoption; it will require robust Medical Affairs engagement to generate RWE, educate on initiation and retention protocols, and guide appropriate use. Competitive dynamics are tightening as alternative extended-release buprenorphine options scale, raising the stakes on contracting, outcomes-based arrangements, and service layers like patient support and distribution.
What to watch in 2026: whether mid-teens Sublocade unit growth materializes beyond core specialty centers into primary care and justice health, whether operating expenses stay within the $430–$450 million guardrail as field and hub investments expand, and whether cash from operations approaches the targeted ~$300 million without eroding gross-to-net. The $400 million buyback signals capital confidence, but the bigger strategic swing may be business development—adjacent addiction, psychiatry, or LAI platform assets that diversify revenue while leveraging the same market access and care delivery infrastructure. The decisive test is whether Indivior can turn category leadership into a defensible ecosystem for OUD care that competitors struggle to dislodge.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
